A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)

ABMMNC therapy is safe and improves symptoms, quality of life, and possibly perfusion in patients with chronic HF.